Table 2.
Tumor response in patients of the two treatment groups
| Variable | Immunotherapy group (n = 100) | Control group (n = 102) | P |
|---|---|---|---|
| Efficacy | |||
| ORR | 54 | 48 | 0.324 |
| % (95% CI) | 54.0 (43.7–64.0) | 47.1 (37.1–57.2) | |
| DCR | 93 | 98 | 0.335 |
| % (95% CI) | 93.0 (86.1–97.1) | 96.1 (90.3–98.9) | |
| Best response, n (%) | |||
| CR | 3 (3.0%) | 2 (2.0%) | |
| PR | 51 (51.0%) | 46 (45.1%) | |
| SD | 39 (39.0%) | 50 (49.0%) | |
| PD | 2 (2.0%) | 2 (2.0%) | |
| NE | 5 (5.0%) | 2 (2.0%) | |
| Median DOR, months (95% CI) | 13.4 (9.8–17.0) | 7.0 (5.9–8.1) | 0.011 |
Control group, XELOX plus bevacizumab; Immunotherapy group, XELOX plus bevacizumab and PD-1 blocked-activated DC-CIK cells
ORR objective response rate, DCR disease control rate, CR complete response, PR partial response, SD stable disease, PD progressive disease, NE not evaluated, DOR duration of response